Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
We may have one thing in common with jellyfish, new research finds - 26 Monetary Arranging Administrations for Your Necessities
- 3UN panel says Israel operating 'de facto policy of torture'
- 4French high-speed train slams into truck, killing TGV driver
- 5A hospital discharged a woman in labor. This lawmaker wants change.
- A 'rampaging lion' nebula roars to life in a stunning deep-space photo
- Instructions to Keep up with Your Traded Teeth for Life span
- This Miraculous, Cliff-Perched Town In The South Of France Is A Sacred European Gem
- Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
- What happened in 'Wicked' part 1 and will there be a 3rd movie? Recap and what Ariana Grande, Jon M. Chu have said about a sequel.
- Choosing Moving Styles for Your Restroom Redesign
- Creative Tech Contraptions That Will Work on Your Life
- How Deforestation Is Reshaping Mosquito-Human Contact
- These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E
